Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

Inclusion Criteria

• •Participants with an endoscopically confirmed diagnosis of active moderate to severe Ulcerative colitis (UC).
• •Participants initiating Upadacitinib (UPA) at the investigator's discretion as part of their routine clinical care; the decision to administer UPA must be made prior to and independent of documentation for the study and according to the approved local label.
• •Participants able to understand and communicate with the investigator and comply with the requirements of the study.
• •Participants willing to continue with study documentation after cessation of UPA.